These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29289837)

  • 1. Double sword role of EZH2 in leukemia.
    Safaei S; Baradaran B; Hagh MF; Alivand MR; Talebi M; Gharibi T; Solali S
    Biomed Pharmacother; 2018 Feb; 98():626-635. PubMed ID: 29289837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.
    Sashida G; Iwama A
    Int J Hematol; 2017 Jan; 105(1):23-30. PubMed ID: 27830540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 in normal and malignant hematopoiesis.
    Lund K; Adams PD; Copland M
    Leukemia; 2014 Jan; 28(1):44-9. PubMed ID: 24097338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic roles of enhancer of zeste homolog 1/2 in hematological malignancies.
    Nakagawa M; Kitabayashi I
    Cancer Sci; 2018 Aug; 109(8):2342-2348. PubMed ID: 29845708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EZH2 in normal hematopoiesis and hematological malignancies.
    Herviou L; Cavalli G; Cartron G; Klein B; Moreaux J
    Oncotarget; 2016 Jan; 7(3):2284-96. PubMed ID: 26497210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of enhancer of zeste homolog 2: From viral epigenetics to the carcinogenesis of hepatocellular carcinoma.
    Sanna L; Marchesi I; Melone MAB; Bagella L
    J Cell Physiol; 2018 Sep; 233(9):6508-6517. PubMed ID: 29574790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
    Christofides A; Karantanos T; Bardhan K; Boussiotis VA
    Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression.
    Cai L; Wang Z; Liu D
    Tumour Biol; 2016 May; 37(5):6359-69. PubMed ID: 26631032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ezh2 regulates the Lin28/let-7 pathway to restrict activation of fetal gene signature in adult hematopoietic stem cells.
    Oshima M; Hasegawa N; Mochizuki-Kashio M; Muto T; Miyagi S; Koide S; Yabata S; Wendt GR; Saraya A; Wang C; Shimoda K; Suzuki Y; Iwama A
    Exp Hematol; 2016 Apr; 44(4):282-96.e3. PubMed ID: 26773568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner.
    Mochizuki-Kashio M; Aoyama K; Sashida G; Oshima M; Tomioka T; Muto T; Wang C; Iwama A
    Blood; 2015 Sep; 126(10):1172-83. PubMed ID: 26219303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [EZH2 is therapeutic target for personalized treatment in multiple myeloma].
    Herviou L; Cavalli G; Moreaux J
    Bull Cancer; 2018 Sep; 105(9):804-819. PubMed ID: 30041976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation.
    Gu Z; Liu Y; Cai F; Patrick M; Zmajkovic J; Cao H; Zhang Y; Tasdogan A; Chen M; Qi L; Liu X; Li K; Lyu J; Dickerson KE; Chen W; Ni M; Merritt ME; Morrison SJ; Skoda RC; DeBerardinis RJ; Xu J
    Cancer Discov; 2019 Sep; 9(9):1228-1247. PubMed ID: 31189531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?
    Yan KS; Lin CY; Liao TW; Peng CM; Lee SC; Liu YJ; Chan WP; Chou RH
    Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.
    Khan SN; Jankowska AM; Mahfouz R; Dunbar AJ; Sugimoto Y; Hosono N; Hu Z; Cheriyath V; Vatolin S; Przychodzen B; Reu FJ; Saunthararajah Y; O'Keefe C; Sekeres MA; List AF; Moliterno AR; McDevitt MA; Maciejewski JP; Makishima H
    Leukemia; 2013 Jun; 27(6):1301-9. PubMed ID: 23486531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms.
    Rinke J; Müller JP; Blaess MF; Chase A; Meggendorfer M; Schäfer V; Winkelmann N; Haferlach C; Cross NCP; Hochhaus A; Ernst T
    Leukemia; 2017 Sep; 31(9):1936-1943. PubMed ID: 28626218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia.
    Danis E; Yamauchi T; Echanique K; Zhang X; Haladyna JN; Riedel SS; Zhu N; Xie H; Orkin SH; Armstrong SA; Bernt KM; Neff T
    Cell Rep; 2016 Mar; 14(8):1953-65. PubMed ID: 26904942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
    Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
    Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
    Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
    J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
    Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2 deletion promotes spermatogonial differentiation and apoptosis.
    Jin C; Zhang Y; Wang ZP; Wang XX; Sun TC; Li XY; Tang JX; Cheng JM; Li J; Chen SR; Deng SL; Liu YX
    Reproduction; 2017 Nov; 154(5):615-625. PubMed ID: 28982932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.